Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,330 total articles
Creative Realities, Inc. announced strong second quarter fiscal 2026 results, showcasing significant revenue growth to $21.5 million from $13.0 million a year prior, driven by the acquisition of Cineplex Digital Media and increased service revenue. The company secured a major contract with a national grocery chain to deploy a Retail Media Network, …
GDS Holdings Limited announced solid financial results for Q2 2026, with a 6.5% year-over-year increase in net revenue to RMB3,088 million and a net income of RMB837.6 million, a significant improvement from a net loss in the prior year. The company saw growth in total area committed, area utilized, and data centers in service, driven by increased …
CorMedix Therapeutics reported strong financial results for Q2 2026, showing consolidated revenue of $101.9 million, net income of $26.0 million, and adjusted EBITDA of $58.7 million, driven by product sales including DefenCath and the acquired Melinta portfolio. The company maintained full-year 2026 revenue guidance and raised its adjusted EBITDA …
Ascendis Pharma reported a remarkable 105% year-over-year increase in Q2 2026 product revenue to €315 million, driven primarily by strong patient demand for its TransCon products YORVIPATH, SKYTROFA, and newly launched YUVIWEL. The company achieved profitability with an operating profit of €220 million and net profit of €207 million. Key clinical a…
UTStarcom Holdings Corp. announced a change in its finance leadership. CFO Dan Xie will step down from his role effective August 21, 2026, moving to Vice President overseeing India and Japan operations. Ying Kang joins as Assistant Vice President of Finance and will take full control of the finance department starting August 21, 2026. The changes w…
Liminatus Pharma, a biopharmaceutical company, announced its stock was transferred to the Nasdaq Capital Market and that it received an extension until September 3, 2026, to regain compliance with Nasdaq's minimum bid price requirement. The company intends to take necessary actions to comply while continuing its clinical development in cancer thera…
Cellectar Biosciences reported strong second quarter 2026 results, highlighted by initiation of site activation for the confirmatory Phase 3 trial of iopofosine I 131 in Waldenström Macroglobulinemia, planned NDA submission under FDA's Accelerated Approval Program in mid-2027, positive Phase 2b CLOVER WaM data, and ongoing Phase 1b trial enrollment…
Caliber (Nasdaq: CWD) announced the launch of its PURE Pickleball & Padel real estate investment offering on its platform as the first to be tokenized, utilizing blockchain technology to improve transparency, investor experience, and liquidity. This initiative uses Chainlink's Automated Compliance Engine for investor verification and compliance. Th…
Pelthos Therapeutics announced its Q2 2026 financial results highlighting a 45% quarter-over-quarter increase in net product revenue for Zelsuvmi, reaching $15.4 million. The company has surpassed 25,000 patients prescribed since launching Zelsuvmi in July 2025 and expects continued growth. It secured a $50 million credit facility to support commer…
POET Technologies Inc. reported a 112% year-over-year revenue increase in Q2 2026, marking its sixth consecutive quarter of sequential growth. The net loss narrowed compared to prior quarters, bolstered by a substantial $400 million financing completed in May, enhancing the company's balance sheet and enabling manufacturing capacity expansion. POET…
Biomea Fusion announced dosing the first participant in a new arm of the OPAL adaptive platform trial that evaluates icovamenib in combination with low-dose semaglutide in overweight or obese individuals without type 2 diabetes. The study aims to assess if adding icovamenib to semaglutide improves weight loss, physical function, body composition, m…
Sagimet Biosciences received FDA clearance and a 'Study May Proceed' letter for its Phase 3 clinical trial of denifanstat, an oral FASN inhibitor targeting moderate to severe acne. The multi-center, randomized, double-blind trial will enroll approximately 800 U.S. patients, including adolescents, with dosing expected to start in the second half of …
Profusa, Inc., a digital health company trading on Nasdaq under PFSA, announced a one-for-four reverse stock split effective August 17, 2026, consolidating every four shares into one to reduce outstanding shares and maintain compliance with Nasdaq listing requirements. The company's authorized shares remain unchanged, and fractional shares will be …
Beyond Air, Inc. announced its Q2 2026 financial results with revenue of $1.8 million and a net loss of $7.9 million. The company reaffirmed its revenue guidance of $8 million for 2026 and $16-$18 million for 2027, anticipating more than 110% growth with the launch of its second-generation LungFit PH system pending FDA approval. The company recentl…
Telesat Corporation reported Q2 and H1 2026 results showing decreased revenue and EBITDA primarily due to challenges in its GEO segment and higher expenses from debt refinancing. The company announced a $2.7 billion contract with the Canadian government to provide military Arctic connectivity via its LEO Lightspeed constellation, prompting a 44% in…
Lantronix Inc., a leader in Edge AI and Industrial IoT solutions, will report its fiscal 2026 fourth quarter results on August 26, 2026, after market close. The company will host an investor conference call and webcast on the same day to discuss the results.
Lotus Technology Inc., a global provider of intelligent and luxury mobility solutions specializing in luxury lifestyle electric vehicles, announced it will report its unaudited financial results for the first half of 2026 on August 27, 2026. The management will hold an earnings conference call and webcast for investors. The company operates across …
Indaptus Therapeutics announced its second quarter 2026 financial results showing reduced net losses and expenses primarily due to discontinuation of its Decoy20 clinical development program and headcount reductions. The company raised $12 million in a private placement to strengthen its liquidity. Indaptus is conducting a strategic review focusing…
SOLV Energy, Inc. reported record second quarter 2026 financial results highlighted by a 77% year-over-year revenue increase to $951 million and strong adjusted EBITDA of $117 million. The company closed the acquisition of Roberson Waite Electric, expanding its capabilities in utility substation construction. With a backlog up 44% year-over-year to…
Xanadu Quantum Technologies has entered a strategic research partnership with the University of Alberta to develop quantum computing algorithms aimed at accelerating discovery of next-generation photosensitizers for photodynamic cancer therapy. This collaboration seeks to leverage quantum computing to overcome current limitations in drug discovery …
Rocket Lab Corporation has reached important milestones in its planned acquisition of Iridium Communications, including the lapse of the Hart-Scott-Rodino antitrust waiting period, filing a Form S-4 registration statement with the SEC, and submitting FCC applications to transfer control of Iridium's licenses. The company is advancing its capital st…
Rocket Lab Corporation has entered into a replacement at-the-market equity distribution agreement to offer up to $1.94 billion of common stock, replacing its prior agreement. The company plans to use net proceeds primarily to fund cash payments for its proposed acquisition of Iridium Communications and to reduce debt commitments. The offering is no…
American Shared Hospital Services (AMS) reported a 19% increase in total revenue to $8.4 million in Q2 2026, fueled by a 40% rise in Direct Patient Services revenue and 22% growth in Proton Beam Radiation Therapy. The company generated $4.4 million in operating cash flow in the first half of 2026 and strengthened its cash position to $6.8 million. …
Pyxis Oncology reported its Q2 2026 financial results and highlighted progress in its MICVO clinical programs targeting recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The company completed a private placement raising approximately $50 million upfront, extending its cash runway into Q2 2027. Updated data from Phase 1 monothe…
Zenas BioPharma announced FDA acceptance of its Biologics License Application (BLA) for obexelimab treating IgG4-Related Disease, with a PDUFA target action date of May 27, 2027. The company confirmed bioequivalence of obexelimab delivery methods, plans a European submission, and expects Phase 2 topline data for Systemic Lupus Erythematosus in Q4 2…
